title: Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein Barr virus-linked lymphoma.
authors.forename: Anne
authors.initials: A
authors.lastname: Sirvent-Von Bueltzingsloewen
authors.forename: Nicolas
authors.initials: N
authors.lastname: Sirvent
authors.forename: Patrice
authors.initials: P
authors.lastname: Morand
authors.forename: Jill Patrice
authors.initials: JP
authors.lastname: Cassuto
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002675:Child, Preschool; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects*; D004273:DNA, Neoplasm / Q000032:analysis; D004279:DNA, Viral / Q000032:analysis; D004660:Encephalitis / Q000209:etiology* / Q000473:pathology / Q000821:virology; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000209:etiology; D017809:Fatal Outcome; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000472:pathogenicity; D006801:Humans; D017403:In Situ Hybridization; D015477:Leukemia, Myelomonocytic, Chronic / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000209:etiology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D016133:Polymerase Chain Reaction; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D004279:DNA, Viral; D000069283:Rituximab